Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

  • Kala Pharmaceuticals Inc (NASDAQ:KALAreported data from a Phase 1b trial of KPI-012, a cell-free secretome therapy for severe ocular diseases driven by impaired healing. 
  • As previously disclosed, KPI-012 was well tolerated and resulted in significant improvements in various persistent corneal epithelial defect (PCED) etiologies. 
  • The data will be presented at the 2022 Association for Research in Vision and Ophthalmology.
  • KPI-012 resulted in the complete healing of PCED in 6 of 8 participants. 
  • Improvement in PCED lesion size was observed in those participants who did not heal completely.
  • All six healed participants remained healed through the end of the follow-up.
  • Related: This Microcap Pharma Stock Almost Doubled Today - Read Why.
  • Participants had a mean (SD) improvement in lesion size of -16.23 (12.38) mm2.
  • The mean improvement in BCDVA was -0.38 (0.88) logMAR.
  • 5 of 8 participants (62.5%) improved their corneal opacity scores from baseline to end of treatment, and 1 had no change in score.
  • 100% reported pain reduction by Week 1. There was only one TEAE reported, and it was mild and transient
  • The company is on track to submit FDA Investigational New Drug Application (IND) and initiate the Phase 2/3 Trial in 4Q 2022.
  • Price Action: KALA shares are up 9.31% at $0.71 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.